Table 1. Patient clinical and demographic characteristics.
| Number of patients | Percent | ||
|---|---|---|---|
| 30 | 100 | ||
| Age (years) | Median | 69 | |
| Sex | Male | 23 | 77 |
| Sex | Female | 7 | 23 |
| Smoke | Never smoker | 8 | 27 |
| Former smoker | 22 | 73 | |
| Histology | Adenocarcinoma | 21 | 70 |
| Squamous cell | 8 | 27 | |
| Large cell | 1 | 3 | |
| EGFR status | Wild type | 26 | 87 |
| Mutant | 4 | 13 | |
| ALK | Wild-type | 30 | 100 |
| Performance status | ECOG 0 | 4 | 13 |
| ECOG 1 | 24 | 80 | |
| ECOG 2 | 2 | 7 | |
| Disease sites | Lung | 27 | 90 |
| Nodes | 9 | 30 | |
| Brain | 8 | 27 | |
| Bone | 9 | 30 | |
| Pleura | 2 | 6 | |
| Liver | 4 | 13 | |
| Peritoneum | 1 | 3 | |
| Previous treatments | First-line chemotherapy | 30 | 100 |
| Cisplatin-based | 28 | 94 | |
| Single-agent | 2 | 6 | |
| Second-line therapy | 30 | 100 | |
| Nivolumab | 29 | 97 | |
| Pembrolizumab | 1 | 3 |